Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection-Reference-Cited by-同舟云学术

Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection

Published:2022-07-12 Issue:8 Volume:36 Page:
ISSN:0887-8013
Container-title:Journal of Clinical Laboratory Analysis
language:en
Short-container-title:Clinical Laboratory Analysis

Author:

Yokoyama Yuta¹²^ORCID,Nozawa Eiji¹,Morita Miho¹,Ishikawa Emi²,Mori Takehiko³⁴,Sakurai Masatoshi³,Kikuchi Taku³,Matsuki Eri³,Yamazaki Rie³⁵,Kataoka Keisuke³,Jibiki Aya¹,Kawazoe Hitoshi¹²,Suzuki Sayo¹²,Nakamura Tomonori¹²

Affiliation:

1. Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences Keio University Faculty of Pharmacy Tokyo Japan

2. Division of Pharmaceutical Care Sciences Keio University Graduate School of Pharmaceutical Sciences Tokyo Japan

3. Division of Hematology, Department of Medicine Keio University School of Medicine Tokyo Japan

4. Department of Hematology Tokyo Medical and Dental University Tokyo Japan

5. Center for Transfusion Medicine and Cell Therapy, Department of Medicine Keio University School of Medicine Tokyo Japan

Publisher

Wiley

Subject

Microbiology (medical),Biochemistry (medical),Medical Laboratory Technology,Clinical Biochemistry,Public Health, Environmental and Occupational Health,Hematology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcla.24598

Reference28 articles.

1. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase

2. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

3. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

4. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

5. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the role of NLRP3 inflammasome activation in new-generation BCR-ABL1 tyrosine kinase inhibitors-induced hepatotoxicity;Toxicology Letters;2024-10

2. Simultaneous determination of three tyrosine kinase inhibitors and three triazoles in human plasma by LC-MS/MS: applications to therapeutic drug monitoring and drug-drug interaction studies;Journal of Chromatography B;2024-10

3. Supramolecular fluorescence sensor array used for the analysis of tyrosine kinase inhibitors in biological fluids and cell imaging;Analytica Chimica Acta;2024-01

4. A Concise Review on Analytical Methods for Determination of Nilotinib;Current Analytical Chemistry;2023-08

5. DIFFERENT ANALYTICAL TECHNIQUES FOR THE ANALYSIS OF ANTICANCER DRUGS-BOSUTINIB, ENCORAFENIB AND DABRAFENIB-A REVIEW;International Journal of Current Pharmaceutical Research;2023-01-15